Xenon Pharmaceuticals Inc. (XENE): Total Assets
$633.16M
As of 2025-12-31
$1.30B
As of 2026-06-30
-5.7%
3-year compound annual growth
+27.3%
5-year compound annual growth
+25.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $633.16M | -20.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $798.14M | -17.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $964.80M | +27.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $754.15M | +31.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $572.01M | +202.4% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $189.19M | +28.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $147.70M | +20.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $122.43M | +165.4% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $46.12M | -31.7% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $67.49M | +5.5% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $63.95M | -26.8% | 2017-03-08, Balance as of period end |
| 2014-12-31 | $87.42M | +60.4% | 2016-03-08, Balance as of period end |
| 2013-12-31 | $54.49M | n/a | 2015-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $56.75M | -43.0% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
Compare XENE, ADAG, BOLT, OVID side by side · Screen every company in Pharmaceutical Preparations ↗